Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1748-717X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma ; volume:11 ; number:1 ; day:18 ; month:5 ; year:2016 ; pages:1-9 ; date:12.2016
Radiation oncology ; 11, Heft 1 (18.5.2016), 1-9, 12.2016
- Urheber
-
Leung, Henry W. C.
- Beteiligte Personen und Organisationen
-
Liu, Chung-Feng
Chan, Agnes L. F.
SpringerLink (Online service)
- DOI
-
10.1186/s13014-016-0644-4
- URN
-
urn:nbn:de:1111-201605197725
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Leung, Henry W. C.
- Liu, Chung-Feng
- Chan, Agnes L. F.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
Survival Outcome Analysis of Stereotactic Body Radiotherapy and Immunotherapy (SBRT-IO) versus SBRT-Alone in Unresectable Hepatocellular Carcinoma
Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure
Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis
Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study
Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis
External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China
SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience
Mean Platelet Volume and Unresectable Hepatocellular Carcinoma
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
Survival Outcome Analysis of Stereotactic Body Radiotherapy and Immunotherapy (SBRT-IO) versus SBRT-Alone in Unresectable Hepatocellular Carcinoma
Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure
Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis
Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study
Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis
External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China
SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience
Mean Platelet Volume and Unresectable Hepatocellular Carcinoma
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
Survival Outcome Analysis of Stereotactic Body Radiotherapy and Immunotherapy (SBRT-IO) versus SBRT-Alone in Unresectable Hepatocellular Carcinoma
Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure
Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis
Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study
Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis
External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China
SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience
Mean Platelet Volume and Unresectable Hepatocellular Carcinoma